Sapporo Clinical Laboratory (TSE:9776) ROCE %: 5.86% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:9776 Sapporo Clinical Laboratory Inc TSE:9776
43 GF Score
Price 円1,960.00
GF Value 円1,041.47
! 4 Warning Signs
View Full Analysis

What is Sapporo Clinical Laboratory ROCE %?

Sapporo Clinical Laboratory TSE:9776 43 ROCE % is 5.86% as of Sep. 2025. GuruFocus rates TSE:9776 with a GF Score™ of 43/100 and a GF Value™ of 円1,041.47. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sapporo Clinical Laboratory's annualized ROCE % for the quarter that ended in Sep. 2025 was 5.86%.

Sapporo Clinical Laboratory  (TSE:9776) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sapporo Clinical Laboratory ROCE % Related Terms

Sapporo Clinical Laboratory ROCE % Historical Data

* Premium members only.

The historical data trend for Sapporo Clinical Laboratory's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sapporo Clinical Laboratory ROCE % Chart

Sapporo Clinical Laboratory Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.69 12.45 7.41 4.55 5.29

Sapporo Clinical Laboratory Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.87 3.23 5.23 5.42 5.86
TSE:9776
43GF Score
Sapporo Clinical Laboratory Inc TSE:9776
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sapporo Clinical Laboratory ROCE % Calculation

Sapporo Clinical Laboratory's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=706.461/( ( (16680.947 - 3307.133) + (16450.937 - 3121.127) )/ 2 )
=706.461/( (13373.814+13329.81)/ 2 )
=706.461/13351.812
=5.29 %

Sapporo Clinical Laboratory's ROCE % of for the quarter that ended in Sep. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2025 )  (Q: Mar. 2025 )(Q: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2025 )  (Q: Mar. 2025 )(Q: Sep. 2025 )
=785/( ( (16450.937 - 3121.127) + (16786.417 - 3304.826) )/ 2 )
=785/( ( 13329.81 + 13481.591 )/ 2 )
=785/13405.7005
=5.86 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.86% mean?
Sapporo Clinical Laboratory (TSE:9776) has a ROCE % of 5.86% as of Sep. 2025.
Is Sapporo Clinical Laboratory's ROCE % too high?
Sapporo Clinical Laboratory's current ROCE % is 5.86%. The Healthcare Providers & Services industry median ROCE % is 6.36. Sapporo Clinical Laboratory's value of 5.86% is 7.9% below this industry median. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's ROCE % compare to competitors?
Sapporo Clinical Laboratory's ROCE % of 5.86% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.36. Sapporo Clinical Laboratory's value of 5.86% is 7.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.36, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sapporo Clinical Laboratory's current ROCE % of 5.86% is 7.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current ROCE % is 5.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current ROCE % of 5.86%. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current ROCE % is 5.86% and 7.9% below the Healthcare Providers & Services industry median of 6.36. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current ROCE % is 5.86% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?

Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued. The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.

Key valuation signals for TSE:9776:

  • ROCE %: 5.86%
  • GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
  • GF Score™: 43/100 with 4 warning signs
  • Industry Position: 7.9% below the Healthcare Providers & Services median

No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sapporo Clinical Laboratory Business Description

Address 18-9-1 Nishi Kita-Gojo, Chuo-ku Sapporo, Hokkaido, Sapporo, JPN, 060 0005
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score

Get the complete analysis for TSE:9776

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,960.00
Price
円1,041.47
GF Value